PTEN and prostate cancer: Encouragingly, the dual mTORC1/2 inhibitor AZD8055 (discontinued) can significantly inhibit cell growth in rapamycin-resistant PTEN-deficient prostate cancer cells in vitro [236], and the dual mTORC1/2 inhibitors vistusertib (AZD2014), RapaLink-1 and sapanisertib (INK-128, MLN0128) are reported to significantly decrease tumor growth in PTEN-deficient prostate cancers in patient-derived xenograft and/or transgenic mouse models, further adding to the appeal of targeting mTORC1/2 clinically [237,238,239].